Atorvastatin Effect on Reduction of COPD Exacerbations

Launched by MEDICAL UNIVERSITY OF BIALYSTOK · Mar 4, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the medication atorvastatin may help reduce inflammation and the frequency of flare-ups in patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung condition that can make it hard to breathe, and flare-ups can lead to worsening symptoms and hospital visits. The trial will involve various hospitals in Poland and aims to see if atorvastatin can improve the health of patients with COPD and identify specific markers that might help tailor treatment for individuals.

To participate in this study, you must be 40 years or older, have a stable form of COPD with certain levels of airflow limitation, and have experienced at least two moderate to severe flare-ups in the past year. Current or former smokers with a history of smoking are also eligible. If you join the trial, you will be randomly assigned to receive either atorvastatin or a placebo (a look-alike pill that contains no active medication) for a set period. Throughout the study, your health will be monitored closely to assess how the treatment affects your condition. It’s important to know that there are certain health conditions and medications that would prevent you from participating, so discussing your eligibility with your doctor is crucial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject has signed Informed Consent Form and is able to understand the purpose and procedures required for the study and is willing to participate in the study.
• • 2. Subject \[male or female\] is aged 40 years and older.
• • 3. Subject is able to understand and comply with the protocol requirements and instructions and is likely to complete the study as planned.
• • 4. Patients with stable COPD with persistent airflow limitation (stable COPD (post-bronchodilator FEV1\<80% of the predicted normal and post-bronchodilator FEV1/FVC\<0,70 at visit 1.) Stage II- IV) and with moderate to very severe airflow limitation according to GOLD guidelines.
• • 5. At least two moderate/severe COPD exacerbations, or at least one leading to hospitalization or ICU admission within 12 months, preceding screening visit.
• • 6. Current or ex-smokers who have a smoking history of at least 10 pack years.
• Exclusion Criteria:
• • 1. Contraindication to statin therapy included but not limited to: known poliomyelitis, motor neuron disease, cranial or temporal arteritis, stroke or myopathy.
• • 2. Statin use within the last 3 months prior to study start.
• • 3. Prior diagnosis of statin induced myopathy or hypersensitivity reaction to another HMG-CoA-reductase inhibitor.
• • 4. Using e-cigarettes or I IQOS tobacco heating system.
• • 5. Pregnant or nursing (lactating) women.
• • 6. Women of child bearing potential, unless they are using effective method of contraception during dosing of study treatment.
• • 7. Patient with a clinically significant abnormality at visit 1 in investigator opinion.
• • 8. Patients with a clinically relevant laboratory abnormality at visit 1 in investigator opinion.
• • 9. Patients with a history of malignancy of any organ system (including lung cancer).
• • 10. Patients unable to perform acceptable spirometry and lung volumes procedures.
• • 11. Patients who had a COPD exacerbations that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the 6 weeks prior to visit 1.
• • 12. Patients who have had a respiratory tract infection within 4 weeks prior to visit1.
• • 13. Patients requiring oxygen therapy (\>15hr/day) on a daily basis for chronic hypoxemia.
• • 14. Patients with a history of asthma or onset of symptoms prior to age 40 years
• • 15. Patients with concomitant pulmonary disease (e.g. lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, tuberculosis).
• • 16. Patients with primary bronchiectasis.
• • 17. Patients with a diagnosis of α-1 antitrypsin deficiency (AATD).
• • 18. Patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation.
• • 19. Active abuse of drugs or alcohol, poor compliance anticipated.
• • 20. Use concomitant medications that are known to interact with atorvastatin: warfarin and other coumarin (vitamin K antagonists) anticoagulants, cyclosporin, gemfibrozil or other non or selective nonsteroidal anti-inflammatory drugs, proton pump inhibitors (PPIs) used by last 6 months.
• • 21. Patients participating in or planning to participate in the active phase of a supervised pulmonary rehabilitation program during the study.
• • 22. Use of other investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening visit.
• • 23. Those unable in the opinion of the Investigator to comply fully with the study requirements.